Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zantac 75 sales reach $46 mil. in second quarter; OTC Tagamet sales $23 mil. worldwide.

This article was originally published in The Tan Sheet

Executive Summary

ZANTAC 75 SECOND QUARTER SALES REACH $46 MIL. in the U.S., and the heartburn remedy has established a "strong number two position" in the OTC H2 antagonist market with a 35% share, Warner-Lambert said July 22. J&J/Merck's Pepcid AC continues as the category leader. Zantac 75 was introduced in the U.S. in late April 1996, and the company recently announced plans to launch the product in Canada, Australia and other European countries ("The Tan Sheet" April 21, p. 10)
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel